<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825302</url>
  </required_header>
  <id_info>
    <org_study_id>PGE2 in asthma</org_study_id>
    <nct_id>NCT03825302</nct_id>
  </id_info>
  <brief_title>Prostaglandin E2 as a Critical Mediator of Sex Disparities in Asthma</brief_title>
  <official_title>Prostaglandin E2 as a Critical Mediator of Sex Disparities in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to understand how biological sex influences airway hyperresponsiveness in
      adult asthma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Provacative dose of mannitol that elicits a 15% decline in forced expiratory volume in males</measure>
    <time_frame>Baseline</time_frame>
    <description>Males only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Provacative dose of mannitol that elicits a 15% decline in forced expiratory volume in females</measure>
    <time_frame>Baseline</time_frame>
    <description>Females only during the luteal phase of the menstrual cycle</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Males with asthma</arm_group_label>
    <description>Induced sputum, methacholine challenge, and mannitol challenge will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Females with asthma</arm_group_label>
    <description>Induced sputum, methacholine challenge, and mannitol challenge will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Methacholine challenge</intervention_name>
    <description>Methacholine inhalation challenge will be administered to both male and females with asthma</description>
    <arm_group_label>Females with asthma</arm_group_label>
    <arm_group_label>Males with asthma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mannitol challenge</intervention_name>
    <description>Mannitol inhalation challenge will be administered to both male and females with asthma</description>
    <arm_group_label>Females with asthma</arm_group_label>
    <arm_group_label>Males with asthma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum, blood, nasal fluid, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Asthmatics at VUMC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be able to understand and provide informed consent

          -  Age 18-50

          -  A history of physician-diagnosed asthma well controlled as assessed by ACQ-6 &lt;1.5 and
             FEV1&gt;70% of predicted and FEV1 &gt;1.5 liters.

          -  Asthma must be persistent, defined by the requirement of a daily controller agent.

          -  Use of a stable dose of daily inhaled corticosteroids for the prior 3 months.

          -  Female subjects of childbearing potential must have a negative pregnancy test upon
             study entry and at each study visit.

        Exclusion Criteria:

          -  Inability or unwillingness of a participant to give written informed consent or comply
             with study protocol.

          -  Hypogonadism, irregular menstrual cycles, polycystic ovarian syndrome (PCOS),
             exogenous hormonal supplements or contraception.

          -  Any chronic lung condition outside of asthma including chronic obstructive pulmonary
             disease (COPD), interstitial lung disease, eosinophilic granulomatosis with
             polyangiitis, allergic bronchopulmonary aspergillosis.

          -  Inability or unwillingness to hold the following medications prior to mannitol and
             methacholine inhalational challenge(s): Short-Acting Beta 2 Agonists &gt;8 hours, Inhaled
             Corticosteroids and Anticholinergic Bronchodilators &gt;12 hours, Phosphodiesterase
             Inhibitors or Adenosine Receptors &gt;24 hours, Long-acting Beta 2 Agonists &gt;36 hours,
             Long-acting Anticholinergics or Short-Acting Antihistamines &gt;48 hours, Long-Acting
             Antihistamines &gt;72 hours, and Leukotriene-Receptor Antagonist or 5-Lipooxygenase
             Inhibitors &gt;4 days.

          -  For males, a screening morning serum total testosterone level (obtained between 8-10
             AM) below the normal reference lab value.

          -  Current pregnancy, breast-feeding, or plans to become pregnant during the study
             period.

          -  Oral or systemic corticosteroid use or biologic agent for asthma in the previous 3
             months or ED/Hospitalization for asthma within 6 months.

          -  Use of investigational drugs within 12 weeks of participation.

          -  Known hypersensitivity or allergy to mannitol, gelatin or methacholine.

          -  Upper or lower respiratory tract infection within the proceeding 6 weeks.

          -  A history of uncontrolled hypertension, coronary artery disease, stroke, epilepsy,
             urinary tract obstruction, untreated thyroid disease, or a chronic lung disease other
             than asthma.

          -  Daily use of a beta-blocker.

          -  Intolerance to anticholinergic medications.

          -  Inability to produce an adequate sputum sample.

          -  Past or current medical problems or findings from physical examination or laboratory
             testing that are not listed above, which, in the opinion of the investigator, may pose
             additional risks from participation in the study, may interfere with the participant's
             ability to comply with study requirements or that may impact the quality or
             interpretation of the data obtained from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Cahill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Cahill, MD</last_name>
    <phone>615-936-2898</phone>
    <email>katherine.cahill@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Katherine Cahill</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

